Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pregabalin + amitriptyline
- Development stage
- Unknown
- Lead developer
- Arrier Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pregabalin + amitriptyline is a fixed-dose combination (FDC) small molecule therapy developed for the management of neuropathic pain. It combines pregabalin, an anticonvulsant that binds to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels to reduce excitatory neurotransmitter release, with amitriptyline, a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine. By targeting both the ascending pain transmission and descending inhibitory pathways, the combination aims to provide superior analgesic efficacy compared to monotherapy. While Arrier Biotech is listed as a distributor of this combination, it is widely available as a generic product in various markets, particularly in India, for conditions such as diabetic peripheral neuropathy and postherpetic neuralgia.
- Other names
- Pregabalin and Amitriptyline combination tablet
02
Targets
SERT (Sodium-dependent serotonin transporter)CACNA2D2 (α2δ-2)NET (Norepinephrine Transporter)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on pregabalin + amitriptyline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pregabalin + amitriptyline.